Author Correction: Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma

被引：0
|
作者：
Jennifer N. Brudno
Norris Lam
Danielle Vanasse
Yueh-wei Shen
Jeremy J. Rose
John Rossi
Allen Xue
Adrian Bot
Nathalie Scholler
Lekha Mikkilineni
Mark Roschewski
Robert Dean
Raul Cachau
Philippe Youkharibache
Rashmika Patel
Brenna Hansen
David F. Stroncek
Steven A. Rosenberg
Ronald E. Gress
James N. Kochenderfer
机构：
[1] Experimental Transplantation and Immunotherapy Branch,
[2] Center for Cancer Research,undefined
[3] National Cancer Institute (NCI),undefined
[4] National Institutes of Health (NIH),undefined
[5] Kite Pharma,undefined
[6] Medical Oncology/Hematology Fellowship Program,undefined
[7] NCI,undefined
[8] Lymphoid Malignancy Branch,undefined
[9] Center for Cancer Research,undefined
[10] NCI,undefined
[11] NIH Bethesda,undefined
[12] Cleveland Clinic Taussig Cancer Center,undefined
[13] Advanced Biomedical Computational Science,undefined
[14] Frederick National Laboratory for Cancer Research,undefined
[15] Cancer Data Science Lab,undefined
[16] Center for Cancer Research,undefined
[17] National Cancer Institute,undefined
[18] National Institutes of Health,undefined
[19] Office of Regulatory Affairs,undefined
[20] NCI,undefined
[21] NIH,undefined
[22] Center for Cellular Engineering,undefined
[23] Clinical Center,undefined
[24] NIH,undefined
[25] Surgery Branch,undefined
[26] Center for Cancer Research,undefined
[27] NCI,undefined
[28] NIH Bethesda,undefined
来源：
Nature Medicine | 2020年 / 26卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
引用
收藏
页码：803 / 803
相关论文
共 50 条
  • [41] CAR-T ENGAGER PROTEINS OPTIMIZE ANTI-CD19 CAR-T CELL THERAPIES FOR LYMPHOMA
    Rennert, Paul
    Su, Lihe
    Wu, Lan
    Lobb, Roy
    Ambrose, Christine
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A187 - A187
  • [42] CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma
    Su, Lihe
    Wu, Lan
    Lobb, Roy R.
    Rennert, Paul D.
    Ambrose, Christine
    ONCOIMMUNOLOGY, 2022, 11 (01):
  • [43] Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
    Ursu, Renata
    Maillet, Didier
    Belin, Catherine
    Moroni, Christine
    Cuzzubbo, Stefania
    Vernier, Victoria
    Sirven-Villaros, Lila
    Carreau, Christophe
    Di Blasi, Roberta
    Thieblemont, Catherine
    Carpentier, Antoine F.
    NEUROLOGY, 2022, 99 (12) : 511 - 515
  • [44] Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
    Cordeiro, Ana Costa
    Durisek, George
    Batista, Marjorie Vieira
    Schmidt, Jayr
    de Lima, Marcos
    Bezerra, Evandro
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [45] A second round of anti-CD19 CAR T-cell therapy in diffuse large B-cell lymphoma: when persistence pays off
    Leroy, Marie
    Deramoudt, Laure
    Pinturaud, Marine
    Demaret, Julie
    Alidjinou, Enagnon Kazali
    Nudel, Morgane
    Cavalieri, Doriane
    Chahla, Wadih Abou
    Odou, Pascal
    Morschhauser, Franck
    Yakoub-Agha, Ibrahim
    Simon, Nicolas
    Beauvais, David
    LEUKEMIA & LYMPHOMA, 2024, 65 (06) : 868 - 871
  • [46] Outcome of Relapsed/Refractory Aggressive B-Cell Lymphoma Patients Relapsing after Anti-CD19 CAR T-Cells and Enrolled in the Descar-T French National Registry
    Di Blasi, Roberta
    Le Gouill, Steven
    Bachy, Emmanuel
    Cartron, Guillaume
    Beauvais, David
    Le Bras, Fabien
    Gros, Francois Xavier
    Choquet, Sylvain
    Bories, Pierre
    Feugier, Pierre
    Casasnovas, Rene-Olivier
    Bay, Jacques-Olivier
    Mohty, Mohamad
    Joris, Magalie
    Gastinne, Thomas
    Sesques, Pierre
    Tudesq, Jean Jacques
    Vercellino, Laetitia
    Morschhauser, Franck
    Gat, Elodie
    Broussais, Florence
    Houot, Roch
    Thieblemont, Catherine
    BLOOD, 2021, 138
  • [47] Anti-CD19 CAR T-Cell (CNCT19) Infusion Following HDT/ASCT Is Safe and Effective in Patients with Relapsed/Refractory Large B-Cell Lymphoma
    Liu, Wei
    Huang, Wenyang
    Lv, Ryu
    Deng, Shuhui
    Yi, Shuhua
    Liu, Huimin
    Lv, Lulu
    Qiu, Lugui
    Zou, Dehui
    Wang, Jianxiang
    BLOOD, 2020, 136
  • [48] Transverse myelitis after anti-CD19 directed CAR T cell therapy for relapsed large B cell lymphoma
    Sheikh, Semira
    Mokhtari, Sepideh
    Silverman, Jeffrey A.
    Reid, Kayla
    Faramand, Rawan
    Davila, Marco L.
    Franke, Norman
    Locke, Frederick L.
    Jain, Michael D.
    Wong, Daniel
    Kuruvilla, John G.
    EJHAEM, 2022, 3 (01): : 223 - 227
  • [49] Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features
    Zhang, Xian
    Lu, Xin-an
    Yang, Junfang
    Zhang, Gailing
    Li, Jingjing
    Song, Lisong
    Su, Yunchao
    Shi, Yanze
    Zhang, Min
    He, Jiujiang
    Song, Dan
    Lv, Fanyong
    Li, Wenqian
    Wu, Yan
    Wang, Hui
    Liu, Hongxing
    Zhou, Xiaosu
    He, Ting
    Lu, Peihua
    BLOOD ADVANCES, 2020, 4 (10) : 2325 - 2338
  • [50] Novel Anti-CD19/Idiotype Bispecific Diabody Vaccine for B-Cell Lymphoma
    Ng, Patrick P.
    Jia, Ming
    Virrueta, Alejandro
    Patel, Kedar
    Swartz, James R.
    Levy, Shoshana
    Levy, Ronald
    BLOOD, 2009, 114 (22) : 1062 - 1062
12345